# Kither Biotech s.r.l.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kither-biotech-s-r-l

- Industry: Pharmaceuticals
- Headquarters: Torino, Italy
- Website: www.kitherbiotech.com
- Total disclosed funding: $27M
- Latest round: Series B (Mar 16, 2022)
- Investors on record: 11

## About

Kither Biotech s.r.l. specializes in developing innovative signal transduction modulators aimed at treating rare respiratory diseases such as cystic fibrosis and idiopathic pulmonary fibrosis, focusing on advanced therapeutic solutions to improve patient outcomes.Founded in 2018, Kither Biotech s.r.l. is based in Torino, Italy. The company focuses on creating therapeutic agents for rare respiratory diseases. The founders, Alessandra Ghigo, Emilio Hirsch, and Marco Malisani, have experience in the biotech sector. Kither Biotech raised EUR 18.5 million in Series B funding on March 16, 2022, co-led by 2Invest and Claris Ventures, with participation from multiple investors, marking a significant investment target for the firm.Kither Biotech develops signal transduction modulators for rare respiratory diseases, particularly cystic fibrosis (CF) and idiopathic pulmonary fibrosis (IPF). Its key products include KIT2014, a small peptide designed as a cAMP modulator with orphan drug designation from the European Medicines Agency, and KITCL27, a small molecule PI3K inhibitor targeting critical enzymatic functions. These therapies are targeted at healthcare providers, hospitals, and specialty clinics, focusing on regions with unmet medical needs in Europe and beyond.In 2023, Kither Biotech reported no revenue, with an EBITDA of EUR -854,041.9, reflecting the company's ongoing investment in research and development rather than immediate revenue generation, as it focuses on bringing its innovative therapies to market.Kither Biotech plans to utilize the EUR 18.5 million raised in Series B funding to support the further development of its lead asset, KIT2014, through to Phase 1/2A clinical trials for cystic fibrosis. The company aims to expand its market presence in Europe and other regions with significant unmet medical needs for rare respiratory diseases, although specific geographical targets and product launch dates have not been disclosed.

## Funding rounds

- Series B, Mar 16, 2022, $20M — CDP Venture Capital, Ersel, Italian Angels for Growth, Club Degli Investitori, 3B Future Health Fund, ACE Ventures, Claris Ventures, 2Invest, Alef 6 S.p.a.
- Series A, Jul 5, 2019, $6.3M — CDP Venture Capital, Ersel, Italian Angels for Growth, Club Degli Investitori, ACE Ventures, Elysia Capital, Moschini

## Investors

- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A, Series B
- Ersel — Series A, Series B
- Italian Angels for Growth (https://capitalatlas.ai/funds/italian-angels-for-growth) — Series A, Series B
- Club Degli Investitori (https://capitalatlas.ai/funds/club-degli-investitori) — Series A, Series B
- ACE Ventures — Series A, Series B
- Elysia Capital — Series A
- Moschini — Series A
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series B
- Claris Ventures (https://capitalatlas.ai/funds/claris-ventures) — Series B
- 2Invest — Series B
- Alef 6 S.p.a. — Series B